Comparative Safety of Pharmacologic Treatments for Persistent Depressive Disorder: A Systematic Review and Network Meta-Analysis.
We aimed to compare the safety of antidepressants for the treatment of persistent depressive disorder (PDD) with each other and with placebo. We conducted a systematic electronic search and included randomized controlled trials that investigated antidepressants for the treatment of PDD in adults. Ou...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2016-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0153380 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849319408482123776 |
|---|---|
| author | Ramona Meister Alessa von Wolff Hannes Mohr Martin Härter Yvonne Nestoriuc Lars Hölzel Levente Kriston |
| author_facet | Ramona Meister Alessa von Wolff Hannes Mohr Martin Härter Yvonne Nestoriuc Lars Hölzel Levente Kriston |
| author_sort | Ramona Meister |
| collection | DOAJ |
| description | We aimed to compare the safety of antidepressants for the treatment of persistent depressive disorder (PDD) with each other and with placebo. We conducted a systematic electronic search and included randomized controlled trials that investigated antidepressants for the treatment of PDD in adults. Outcomes were the incidence of experiencing any adverse event, specific adverse events and related treatment discontinuations. We analyzed the data using traditional and network meta-analyses. Thirty-four studies that comprised 4,769 patients and examined 20 individual agents in nine substance classes were included. Almost all analyzed substance classes were associated with higher discontinuation rates than placebo including tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOIs), antipsychotics, and the serotonin antagonist and reuptake inhibitor (SARI) trazodone. The odds of experiencing any adverse event were significantly higher for TCAs and serotonin noradrenaline reuptake inhibitors (SNRIs) compared to placebo. Pairwise comparisons among the substance classes revealed that more patients receiving TCAs or SNRIs experienced any adverse event and that more patients receiving TCAs or the SARI trazodone discontinued treatment. The complementary treatment with acetyl-l-carnitine showed lower rates of experiencing any adverse event and related discontinuations than all other comparators. TCAs were primarily associated with (anti-)cholinergic and sedating adverse events. SSRIs primarily showed gastrointestinal adverse events. Patients treated with the antipsychotic amisulpride were more likely to manifest weight gain and endocrine adverse events. The comparative evidence for further agents was insufficient or lacking. The identified safety differences may be used to inform the selection among the antidepressants. |
| format | Article |
| id | doaj-art-41b8733c779d4bdaa29d79068512bbca |
| institution | Kabale University |
| issn | 1932-6203 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-41b8733c779d4bdaa29d79068512bbca2025-08-20T03:50:27ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01115e015338010.1371/journal.pone.0153380Comparative Safety of Pharmacologic Treatments for Persistent Depressive Disorder: A Systematic Review and Network Meta-Analysis.Ramona MeisterAlessa von WolffHannes MohrMartin HärterYvonne NestoriucLars HölzelLevente KristonWe aimed to compare the safety of antidepressants for the treatment of persistent depressive disorder (PDD) with each other and with placebo. We conducted a systematic electronic search and included randomized controlled trials that investigated antidepressants for the treatment of PDD in adults. Outcomes were the incidence of experiencing any adverse event, specific adverse events and related treatment discontinuations. We analyzed the data using traditional and network meta-analyses. Thirty-four studies that comprised 4,769 patients and examined 20 individual agents in nine substance classes were included. Almost all analyzed substance classes were associated with higher discontinuation rates than placebo including tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOIs), antipsychotics, and the serotonin antagonist and reuptake inhibitor (SARI) trazodone. The odds of experiencing any adverse event were significantly higher for TCAs and serotonin noradrenaline reuptake inhibitors (SNRIs) compared to placebo. Pairwise comparisons among the substance classes revealed that more patients receiving TCAs or SNRIs experienced any adverse event and that more patients receiving TCAs or the SARI trazodone discontinued treatment. The complementary treatment with acetyl-l-carnitine showed lower rates of experiencing any adverse event and related discontinuations than all other comparators. TCAs were primarily associated with (anti-)cholinergic and sedating adverse events. SSRIs primarily showed gastrointestinal adverse events. Patients treated with the antipsychotic amisulpride were more likely to manifest weight gain and endocrine adverse events. The comparative evidence for further agents was insufficient or lacking. The identified safety differences may be used to inform the selection among the antidepressants.https://doi.org/10.1371/journal.pone.0153380 |
| spellingShingle | Ramona Meister Alessa von Wolff Hannes Mohr Martin Härter Yvonne Nestoriuc Lars Hölzel Levente Kriston Comparative Safety of Pharmacologic Treatments for Persistent Depressive Disorder: A Systematic Review and Network Meta-Analysis. PLoS ONE |
| title | Comparative Safety of Pharmacologic Treatments for Persistent Depressive Disorder: A Systematic Review and Network Meta-Analysis. |
| title_full | Comparative Safety of Pharmacologic Treatments for Persistent Depressive Disorder: A Systematic Review and Network Meta-Analysis. |
| title_fullStr | Comparative Safety of Pharmacologic Treatments for Persistent Depressive Disorder: A Systematic Review and Network Meta-Analysis. |
| title_full_unstemmed | Comparative Safety of Pharmacologic Treatments for Persistent Depressive Disorder: A Systematic Review and Network Meta-Analysis. |
| title_short | Comparative Safety of Pharmacologic Treatments for Persistent Depressive Disorder: A Systematic Review and Network Meta-Analysis. |
| title_sort | comparative safety of pharmacologic treatments for persistent depressive disorder a systematic review and network meta analysis |
| url | https://doi.org/10.1371/journal.pone.0153380 |
| work_keys_str_mv | AT ramonameister comparativesafetyofpharmacologictreatmentsforpersistentdepressivedisorderasystematicreviewandnetworkmetaanalysis AT alessavonwolff comparativesafetyofpharmacologictreatmentsforpersistentdepressivedisorderasystematicreviewandnetworkmetaanalysis AT hannesmohr comparativesafetyofpharmacologictreatmentsforpersistentdepressivedisorderasystematicreviewandnetworkmetaanalysis AT martinharter comparativesafetyofpharmacologictreatmentsforpersistentdepressivedisorderasystematicreviewandnetworkmetaanalysis AT yvonnenestoriuc comparativesafetyofpharmacologictreatmentsforpersistentdepressivedisorderasystematicreviewandnetworkmetaanalysis AT larsholzel comparativesafetyofpharmacologictreatmentsforpersistentdepressivedisorderasystematicreviewandnetworkmetaanalysis AT leventekriston comparativesafetyofpharmacologictreatmentsforpersistentdepressivedisorderasystematicreviewandnetworkmetaanalysis |